POSSIBILITIES OF DYSBIOTIC CHANGES CORRECTION IN PATIENTS WITH JOINTS AND SPINE INJURIES AND INFLAMMATORY BOWEL DISEASES

Zhdan V. M., Kyrian O. A., Babanina M. Yu., Shilkina L. M., Katerenchuk O. I.

CLINICAL AND EXPERIMENTAL MEDICINE

Scentific article

The goal of our research was to study the efficiency of safe probiotic Bacillus clausii administration in correction of dysbiotic changes in patients with inflammatory bowel diseases when they also have extraintestinal joints and spine injuries. 56 patients with inflammatory bowel diseases who also had extraintestinal injuries of joints and spine were examined and treated. The average age of the patients was 37,4±5,1 years. The duration of the disease was no less than 6 months. The patients were divided into two groups. The first group consisted of 26 (46,4%) patients who were prescribed the Bacillus clausii probiotic in addition to the standard medication. There were 30 (53,6%) patients in the second group who underwent the standard drug treatment without probiotics, prebiotics, and symbiotic. The activity of the inflammatory bowel diseases with extraintestinal injuries was evaluated using non-specific markers such as C-reactive protein, leukocytosis, thrombocytosis, erythrocyte sedimentation rate and considering the calprotectin quantitative content. The profile of the colonic microbiota was studied to determine the efficiency of the Bacillus clausii probiotic in patients with inflammatory bowel diseases and extraintestinal injuries of joints and spine. All patients of the first and second groups had colonic dysbiosis with an increase of the opportunistic microflora and reduction of Lactobacillus. In the first group of patients with inflammatory bowel diseases and extraintestinal joints and spine injuries who received the Bacillus clausii probiotic treatment pain intensity and flatulence (p<0,05) decrease was detected on the 28 day of treatment. Significant reduction of Enteroccocus, Klebsiella, Citrobacter amount (p<0,01) as well as increase of Lactobacillus amount (p<0,05) in the colonic microflora in the first group of patients was detected. These results give an opportunity to recommend the Bacillus clausii probiotic for treatment of patients with inflammatory bowel diseases and extraintestinal joints and spine injuries.

inflammatory bowel diseases, extraintestinal injuries, colonic microflora, osteoarticular system.

1. Kyrian OA. Optymizaciya diagnostychnogo poshuku khvopykh iz nespecyfichnym vyrazkovym kolitom. Skhidnoyevpopejskyj zhurnal vnutrishnoyi ta simejnoyi medycyny. 2019;1:109-13. [in Ukrainian]
2. Khimion LV, Danyliuk SV, Kicha NV, Budko TM. Nespecyfichnyj vyrazkovyj kolit u praktyci simejnogo likarya. Simejna medycyna. 2018;5(79):5-9. [in Ukrainian].
3. Stepanov YuM, Skyrda IYu, Petishko OP. Khronichni zapalni zakhvoryuvannya kyshechnyka: osoblyvosti epidemiologiyi v Ukrayini. Gastpoenterologiya. 2017;51(2):11-9. [in Ukrainian].
4. Zhdan VM, Kyrian OA, Babanina MYu, Shylkina LM, Katerenchuk OI. Osoblyvosti pozakyshkovogo urazhennya oporno-rukhovogo aparatu u khvorykh iz zapalnymy zakhvoryuvannyamy kyshechnyka. Visnyk problem biologiyi i medycyny. 2019;4.1(153):89-93. [in Ukrainian].
5. Hedin CRH, Vavricka SR, Stagg AJ, Schoepfer A, Raine T, Puig L, et al. The Pathogenesis of Extraintestinal Manifestations: Implications for IBD Research, Diagnosis, and Therapy. J Crohns Colitis. 2019 Apr 26;13(5):541-54.
6. Salem F, Kindt N, Marchesi JR, Netter P, Lopez A, Kokten T, et al. Gut microbiome in chronic rheumatic and inflammatory bowel diseases: Similarities and differences. United European Gastroenterol J. 2019 Oct;7(8):1008-32. DOI: 10.1177/2050640619867555
7. Klingberg E, Strid H, Stаhl A, Deminger A, Carlsten H, Öhman L, et al. A longitudinal study of fecal calprotectin and the development of inflammatory bowel disease in ankylosing spondylitis. Arthritis Res Ther. 2017;19:PMC5289027.
8. Breban M, Tap J, Leboime A, Said-Nahal R, Langella P, Chiocchia G, et al. Faecal microbiota study reveals specific dysbiosis in spondyloarthritis. Ann Rheum Dis. 2017 Sep;76(9):1614-22. PMID: 28606969.
9. Tito RY, Cypers H, Joossens M, Varkas G, Van Praet L, Glorieus E, et al. Brief Report: Dialister as a Microbial Marker of Disease Activity in Spondyloarthritis. Arthritis Rheumatol. 2017 Jan;69(1):114-21. PMID: 27390077.
10. Stoll ML, Weiss PF, Weiss JE, Nigrovic PA, Edelheit BS, Bridges SL Jr, et al. Age and fecal microbial strain-specific differences in patients with spondyloarthritis. Arthritis Res Ther. 2018 Jan 30;20(1):14. PMID: 29382366; PMCID: PMC5791354.
11. Dorofeyev AE, Vasilenko IV, Rassokhina OA. Joint extraintestinal manifestations in ulcerative colitis. Dig Dis. 2009;27:502-10. PMID: 19897966.
12. Walujkar SA, Kumbhare SV, Marathe NP, Patangia DV, Lawate PS, Bharadwaj RS, et al. Molecular profiling of mucosal tissue associated microbiota in patients manifesting acute exacerbations and remission stage of ulcerative colitis. World J Microbiol Biotechnol. 2018 May 23;34(6):76. DOI: 10.1007/s11274-018-2449-0. PMID: 29796862.
13. Hirano A, Umeno J, Okamoto Y, Shibata H, Ogura Y, Moriyama T, et al. Comparison of the microbial community structure between inflamed and non-inflamed sites in patients with ulcerative colitis. J Gastroenterol Hepatol. 2018 Feb 20. DOI: 10.1111/jdh.14129. PMID: 29462845.
14. Scher JU, Ubeda C, Artacho A, Attur M, Isaac S, Reddy SM, et al. Decreased bacterial diversity characterizes the altered gut microbiota in patients with psoriatic arthritis, resembling dysbiosis in inflammatory bowel disease. Arthritis Rheumatol. 2015 Jan;67(1):128-39. DOI: 10.1002/art.38892. PMID: 25319745; PMCID: PMC4280348.
15. Stoll ML, Kumar R, Morrow CD, Lefkowitz EJ, Cui X, Genin A, et al. Altered microbiota associated with abnormal humoral immune responses to commensal organisms in enthesitis-related arthritis. Arthritis Res Ther. 2014 Nov 30;16(6):486. DOI: 10.1186/s13075-014- 0486-0. PMID: 25434931; PMCID: PMC4272554.
16. Jacques P, Mc Gonagle D. The role of mechanical stress in the pathogenesis of spondyloarthritis and how to combat it. Best Pract Res Clin Rheumatol. 2014;28:703-10.
17. Park JH, Peyrin-Biroulet L, Eisenhut M, Shin JI. IBD immunopathogenesis: A comprehensive review of inflammatory molecules. Autoimmun Rev. 2017;16:416-26.
18. Dargahi N, Johnson J, Donkor O, Vasiljevic T, Apostolopoulos V. Immunomodulatory effects of probiotics: Can they be used to treat allergies and autoimmune diseases? Maturitas. 2019 Jan;119:25-38. DOI: 10.1016/j.maturitas.2018.11.002. PMID: 30502748.
19. Lopetuso LR, Scaldaferri F, Franceschi F, Gasbarrini A. Bacillus clausii and gut homeostasis: state of the art and future perspectives. Expert Rev Gastroenterol Hepatol. 2016 Aug;10(8):943-8. DOI: 10.1080/17474124.2016.1200465. PMID: 27291780.
20. Abatupov AE, Babych VL. Ymmunotropnoe dejstvye probyotycheskykh shtammov Bacillus clausii. Pedyatryya. Vostochnaya Evpopa. 2016;4(4):532-41. [in Russian].
21. Maaser C, Sturm A, Vavricka SR, Kucharzik T, Fiorino G, Annese V, et al. ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 1: Initial diagnosis, monitoring of known IBD, detection of complications. J Crohns Colitis. 2019 Feb;13(2):144-64.
22. Sturm A, Maaser C, Calabrese Е, Annese V, Fiorino G, Kucharzik T, et al. ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 2: IBD scores and general principles and technical aspects. Journal of Crohn’s and Colitis. 2019 Mar;13(3):273-84.

«Bulletin of problems biology and medicine» Issue 4 (158), 2020 year, 131-136 pages, index UDK 616.34:616.722-002

10.29254/2077-4214-2020-4-158-131-136